Skip to content
Open access

Sex Differences in Coronary Atheroma Regression After Intensive Lipid-Lowering Therapy

Sep 2026 · JACC: Advances · Vol 5, pp. 103243 · 0 citations · 44 references
Medicine

TL;DR

Women undergoing clinically indicated procedures present with paradoxically less extensive atheroma and more favorable plaque composition despite higher cardiovascular risk burden, and experience greater coronary plaque regression than men after intensive lipid-lowering.

Abstract

Background Intensive lipid-lowering therapy with high-intensity statins, with or without proprotein convertase subtilisin/kexin type 9 inhibitors, reduces coronary plaque burden. However, whether men and women experience similar atheroma regression and plaque compositional changes remains uncertain. Objectives The objective of the study was to quantify sex-specific changes in percent atheroma volume (PAV), total atheroma volume (TAV), and plaque composition after intensive lipid-lowering, using pooled individual-participant data from four serial intravascular ultrasound trials. Methods Data from REVERSAL, ASTEROID, SATURN, and GLAGOV trials (N = 2,737; 1,987 men, 750 women) were analyzed centrally. Over a median follow-up of 20.7 months, annualized changes in PAV, TAV, and virtual histology components were compared using linear mixed-effects models adjusted for baseline plaque burden and trial. Results Women were older with higher rates of hypertension and diabetes but presented with lower baseline PAV (mean: 34.5% vs 38.5%) and less extensive plaque composition abnormalities, even when normalized for plaque burden. Virtual histology analysis revealed women had lower baseline fibro-fatty volume (median: 13.7 vs 34.3 mm3), necrotic core volume (median: 7.7 vs 13.1 mm3), and higher fibrous content (mean: 41.5% vs 36.7%). Following treatment achieving similar low-density lipoprotein-cholesterol (LDL-C) (∼70 mg/dL), women showed greater regression in PAV (least-squares-mean: −0.25% vs −0.05%) and TAV, with similar plaque stabilization. Female sex independently predicted PAV regression, which was most pronounced in women achieving LDL-C <55 mg/dL. Conclusions Women undergoing clinically indicated procedures present with paradoxically less extensive atheroma and more favorable plaque composition despite higher cardiovascular risk burden. They experience greater coronary plaque regression than men after intensive lipid-lowering, especially when LDL-C is below 55 mg/dL, with similar plaque stabilization.

Read PDF

Similar papers

Open access Oct 2026

Improved plaque composition from intensive medical treatment in women with angina and non-obstructive coronary disease.

AIMS Among women with suspected ischaemia and non-obstructive coronary artery disease (INOCA), the temporal effect of combination intensive medical treatment (IMT) with angiotensin-converting enzyme inhibitors or receptor blockers, statins, and aspirin on coronary plaque composition is not known. This prospective ancil...

J. Lenell, Guadalupe Flores Tomasino, Donghee Han et al. · 0 citations
Open access Sep 2026

Predicting LDL-cholesterol reduction variability on statin-ezetimibe therapy: insights from "Jena auf Ziel".

Upfront dual therapy with atorvastatin (80 mg) and ezetimibe (10 mg) achieved robust LDL‑C reduction with low interindividual variability in treatment-naive individuals, which supports current guideline recommendations for immediate combination therapy in very high-risk patients, irrespective of their baseline metaboli...

U. Makhmudova, D. Lütjohann, F. Haertel et al. · 0 citations
Open access Oct 2026

Remnant cholesterol, C-reactive protein, cholesterol-lowering medication, and cardiovascular outcome: novel findings from UK Biobank

Findings support combined assessment of both biomarkers for personalized cardiovascular risk stratification and suggest effect modification by cholesterol-lowering medication reduces RC-related risk but not inflammation-driven risk in isolated CRP elevation.

Jing Chen, Xuan-Ceng-Fan-Jiang Song, Jian-Jun Li et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.